section name header

Pronunciation ⬇

tye-ZAN-i-deen

Classifications ⬆ ⬇

Therapeutic Classification: antispasticity agents (centrally acting)

Pharmacologic Classification: adrenergics

Indications ⬆ ⬇

REMS

Action ⬆ ⬇

  • Acts as an agonist at central alpha-adrenergic receptor sites.
  • Reduces spasticity by increasing presynaptic inhibition of motor neurons.
Therapeutic effects:
  • Decreased spasticity, allowing better function.

Pharmacokinetics ⬆ ⬇

Absorption: Completely absorbed after oral administration but rapidly metabolized, resulting in 40% bioavailability.

Distribution: Widely distributed.

Metabolism/Excretion: 95% metabolized by the liver.

Half-Life: 2.5 hr.

Time/Action Profile ⬆ ⬇

(reduced muscle tone)

ROUTEONSETPEAKDURATION
POunknown1–2 hr3–6 hr

Contraind./Precautions ⬆ ⬇

Contraindicated in:

Use Cautiously in:

Exercise Extreme Caution in:

Adv. Reactions/Side Effects ⬆ ⬇

CNS: anxiety, depression, dizziness, sedation, weakness, dyskinesia, hallucinations, nervousness

EENT: blurred vision, pharyngitis, rhinitis

CV: hypotension, bradycardia

GI: abdominal pain, diarrhea, dry mouth, dyspepsia, constipation, hepatocellular injury, ↑liver enzymes, vomiting

GU: urinary frequency

Derm: rash, skin ulcers, sweating

MS: back pain, myasthenia, paresthesia

Misc: fever, speech disorder

Interactions ⬆ ⬇

Drug-drug:

Route/Dosage ⬆ ⬇

Tablets are not interchangeable with capsules

Availability ⬆ ⬇

(Generic available)

Assessment ⬆ ⬇

Lab Test Considerations:

Implementation ⬆ ⬇

Patient/Family Teaching ⬆ ⬇

Evaluation/Desired Outcomes ⬆ ⬇

US Brand Names ⬆ ⬇

Zanaflex

Pot. Nursing Diagnoses ⬆ ⬇

Code ⬆

NDC Code